{"id":"ser120","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by selectively binding to the serotonin receptor, which leads to a decrease in serotonin levels in the brain. This decrease in serotonin levels is thought to be beneficial for patients with certain conditions.","oneSentence":"SER120 is a small molecule that targets the serotonin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:02.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT00981682","phase":"PHASE3","title":"Long Term Safety Assessment of SER120 in Patients With Nocturia","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2009-08","conditions":"Nocturia","enrollment":376},{"nctId":"NCT01259128","phase":"PHASE3","title":"Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2010-04","conditions":"Nocturia","enrollment":32},{"nctId":"NCT01900704","phase":"PHASE3","title":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2013-08","conditions":"Nocturia","enrollment":810},{"nctId":"NCT00937378","phase":"PHASE3","title":"Treatment of Patients With Nocturia (Non-PK Study)","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Nocturia","enrollment":326},{"nctId":"NCT01357356","phase":"PHASE2, PHASE3","title":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2011-05","conditions":"Nocturia","enrollment":750},{"nctId":"NCT00937859","phase":"PHASE3","title":"Treatment of Patients With Nocturia","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Nocturia","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SER120","genericName":"SER120","companyName":"Serenity Pharmaceuticals, Inc.","companyId":"serenity-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SER120 is a small molecule that targets the serotonin receptor. Used for Treatment-resistant depression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}